Safety and Feasibility of Lung Resection after Immunotherapy for Metastatic or Unresectable Tumors.
CONCLUSIONS: In patients with previously metastatic or unresectable cancer, lung resection for suspected residual disease following immunotherapy is feasible, with high rates of R0 resection. Operations can be technically challenging, but significant morbidity appears to be rare. Outcomes are encouraging, with reasonable survivals during short-interval follow-up.
PMID: 29550207 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS Tags: Ann Thorac Surg Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Databases & Libraries | Immunotherapy | Lung Cancer | Melanoma | Skin Cancer | Thoracotomy | Yervoy